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Summary An analysis of prognostic factors has been performed on 260 patients with high and intermediate
grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-
year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and
laboratory parameters have been studied, including variables reported to be important indicators of prognosis
in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment
of complete remission (CR) was the most important predictor of overall survival, low serum lactate
dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated
with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor
clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients
achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced
stage disease, constitutional symptoms, increasing patient age, a lovy serum albumin and the presence of bulk
disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free
survival, and reduced overall survival following CR. There was no significant correlation between histological
subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission
status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and
LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology
NHL.
Over the past decade durable remissions have been achieved
in an increasing proportion of patients with high grade NHL
and there is evidence that remission rates and survival may
be improved by using intensive chemotherapy (Fisher et al.,
1983; Klimo & Collins, 1985; Laurence et al., 1982;
Blackledge et al., 1980). A more aggressive approach to
treatment in this disease is inevitably associated with an
increased toxicity and a greater requirement for supportive
resources. Clearly an accurate pre-treatment prognostic
assessment of patients is required to guide the clinician in the
selection of the most appropriate treatment schedule. Cur-
rently, in high grade NHL, therapeutic policy is determined
predominantly by the extent of disease as defined by the
Ann Arbor staging system (Carbonne et al., 1971), and this
system has continued to be employed despite our recognition
that it harbours some important discrepancies (Rosenberg,
1977). In this study we have set out to reassess the prognos-
tic relevance of the Ann Arbor system in high grade NHL
and, further, have attempted to identify additional patient
characteristics and disease parameters which may be used in
conjunction with the Ann Arbor system to improve our
prognostic evaluation of patients.
Retrospective studies performed over the past 10 years
have reported a number of factors having influence on
prognosis in high grade NHL. However, the interpretation
of data from many series has been hampered by small
patient numbers and the fact that only few centres have
employed multivariate analyses (Jagganath et al., 1985;
Armitage et al., 1982; Steward et al., 1984; Todd et al., 1986;
Shipp et al., 1986; Fisher et al., 1981; Koziner et al., 1982).
Comparison of results from different studies is further
compromised by the lack of uniformity in the variables
analysed, and in many publications the potential prognostic
factors investigated are not clearly listed.
In an attempt to re-examine the prognostic evaluation of
patients, we have collected data, including all variables
previously reported as having significant prognostic import-
ance in high grade NHL, and subjected these data to
multivariate analysis.
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Materials and methods
Patient details
The Manchester Lymphoma Group entered 260 previously
untreated patients in treatment protocols for high grade
NHL between 1975 and 1986. The patient selection criteria
included: age 15-75 years inclusive, no previous treatment
for NHL, no previous history of malignancy and no accom-
panying medical condition which would preclude either
chemotherapy or radiation treatment. The patient details are
shown in Table I. Two hundred and six patients presenting
with Ann Arbor stage II (with bulk nodal involvement),
stage III and IV disease received a 6-week course of
induction chemotherapy with VAP (vincristine, adriamycin
and prednisolone) (Blackledge et al., 1980). The remaining
patients with stage I and II (non-bulky) disease received
initial radiotherapy and were subsequently randomised to
receive either adjuvant VAP or 3-weekly cycles of CMOPP
(cyclophosphamide, mustine, vincristine, procarbazine and
prednisolone) (Wagstaff et al., 1987). Involved field radio-
therapy was given to the original site of disease in patients
with stage I and stage II lymphoma to a dose of 3,000cGy
over 3 weeks. Patients with stage III and IV disease were
given radiotherapy to previously involved bulky sites follow-
ing induction chemotherapy. Those patients in CR received
2,500cGy fractionated over 8 days, whereas patients with
residual tumour following induction chemotherapy received
3,000-3,500cGy with wide margins over 3 weeks. The
median follow-up for the group is 72 months.
All patients were staged using the Ann Arbor system. Pre-
treatment evaluation included a detailed history and physical
examination, a full blood count and ESR, biochemical
profile (including liver enzymes and LDH), a bone marrow
aspirate and trephine from a single site, CSF examination,
chest radiograph and computed tomographic scan (CT) of
the abdomen and pelvis. Laparotomies were not performed
for routine staging purposes, and percutaneous liver biopsy
was undertaken in only a minority of cases. Isotopic bone
scans, abdominal ultrasound scans and barium GI tract
studies were performed when clinically indicated. Bulk dis-
ease was defined as tumour measuring more than 5 cm in
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Table I Patient characteristics (age
years, median 50)
15-75
No. %
Sex
Male
Female
Stage I
Stage II
Stage III
Stage IV
B symptoms
Bulk disease
Extra nodal disease
Bone marrow
Liver
GI tract
Skin
Lung
Karnofsky performance
90
80
70
60
Total
130
130
36
70
35
119
106
142
143
58
52
49
21
18
80
78
52
50
50
50
14
27
13
46
41
55
55
22
20
19
8
7
31
30
20
19
260 100
greatest diameter at commencement of treatment. On com-
pletion of therapy all patients underwent a full restaging
evaluation which included a repeat of initially abnormal
investigations to assess response. At the time of relapse or
progressive disease, patients were treated with a variety of
salvage regimes.
Histology
In all cases histological specimens were reviewed at the
Christie Hospital before treatment, and patients were treated
on protocol if the histology was considered high grade in
either the Rappaport or Kiel classifications. For the purpose
of this publication the histology was re-reviewed by one of
the authors (M.H.) and classified using the Kiel classi-
fication. Conventionally processed wax-embedded sections
were stained with Haematoxylin and Eosin, and in some
cases with Gordon & Sweet's reticulin method, methyl green
pyronine and PAS. Table II shows the distribution of
histology in a modified Kiel system incorporating an inter-
mediate grade (Nanholtz et al., 1987), with corresponding
working formulation terminology (WF) (NHL Pathological
Classification Project, 1982). The 21 cases described as 'true
histiocytic' comprise 14 cases with primary gastrointestinal
involvement, initially diagnosed as 'malignant histiocytosis of
the intestine', but many of these tumours are now recognised
as T-cell in origin (Isaacson et al., 1985). In addition the
diffuse unclassified category includes some cases of probable
T-cell lymphoma, but data from immunophenotyping are
not included in this paper.
Flow cytometric analysis (FCM)
FCM estimation of nuclear DNA content was performed on
wax-embedded tissue from 208 patients. The nuclear suspen-
sions were obtained using the method of Hedley et al.
(1983), and stained with 4',6'-diamidino-2-phenylindole-
dihydrochloride DAPI (Sigma) in RPMI 1640 culture
medium, pH 7.4 at room temperature for 30min; it was
filtered through 35 um nylon gauze before analysis. FCM
analysis was performed using an EPICS V flow cytometer
(Coulter Electronics, FA), with a Spectre Physics 20-20
argon ion laser operating at 150mW ultra-violet, with an
excitation wavelength of 357 nm and an emission fluor-
escence measured at 408nm. A minimum of 30,000 nuclei
were analysed for each tumour.
Statistical analysis
Over 25 potential prognostic factors were studied to assess
their ability to predict clinical outcome in terms of attain-
ment of CR, overall survival, relapse-free survival (RFS) and
survival following the attainment of CR. These variables are
listed in Table III. Survival was calculated from the date of
starting treatment to the last follow-up or death. Relapse-
free survival was defined as the interval between the con-
firmed establishment of CR and the date of documented
relapse. CR was documented by full staging assessment at
completion of therapy.
The prognostic influence of each variable was assessed by
plotting Kaplan-Meier survival curves (Kaplan & Meier,
1958), and these curves were compared using the log rank
test (Peto & Peto, 1972). Cox's proportional hazards model
(Cox, 1972) was used to determine the most important
prognostic variables. A stepwise logistic regression procedure
was performed to determine combinations of patient charac-
teristics and disease parameters important in predicting CR.
The data from continuous variables were examined to ensure
that there was a linear relationship between the absolute
value of the variable and prognosis. Continuous variables
relating to biochemical measurements were transformed by
taking logarithms. Missing covariate data were handled by
the introduction of a dummy variable to indicate the
presence or absence of information on a particular variable.
Results
Factors having a significant relationship with prognosis
(attainment of CR, RFS or survival) using univariate analy-
sis are listed in Table IV. Treatment schedule did not prove
to be a significant prognostic factor in terms of overall
survival, RFS and survival following CR in multivariate
analysis.
Overall survival
The median survival for the 260 patients was 53 months
Table II Histological classification
Kiel Working formulation
No. points %
Intermediate grade
Centroblastic-centrocytic f+d 13 5 Large cell, f+d
Centrocytic (small and large cell) 28 11 Small and large cleaved cell
Centroblastic-centrocytic, d 20 8 Large cell, cleaved, d
High grade
Centroblastic 50 19 Large cell, non-cleaved, d
Lymphoblastic (including Burkitt) 29 11 Lymphoblastic and small non-cleaved
Immunoblastic 47 18 Large cell, immunoblastic
High grade unclassified 52 20
True histiocytic 21 8
Total 260 100
Abbreviations: f, follicular; d, diffuse.278 R.A. COWAN et al.
Table III Potential prognostic factors studied
Clinical parameters
Age
Sex
Karnofsky performance status
Clinical stage (Ann Arbor)
B symptoms
Bulk disease
Number of nodal sites
Number of extra-nodal sites
Radiological parameters
Mediastinal involvement
Pleural involvement
Lung parenchymal involvement
Histology
Histological subtypes (Rappaport and Kiel)
Biochemistry
Serum alkaline phosphatase
Serum aspartate transaminase (AST)
Serum alanine transaminase (ALT)
Serum gamma glutamyl transferase (Gamma
GT)
Serum bilirubin
Serum albumin
Serum sodium
Serum lactate dehydrogenase (LDH)
Haematology
Haemoglobin
Lymphocyte count
Marrow involvement
Erythrocyte sedimentation rate (ESR)
Treatment received
DNA content (flow cytometric analysis)
DNA aneuploidy
Proliferative index (PI)
S-phase %
(Figure 1). In a multivariate analysis, attainment of CR
proved to be the factor most significantly associated with
prolonged survival (Table V). Patients entering CR showed a
5-year survival rate of 64% compared with 24% for the
partial responders, and of the non-responders no patients
were alive at 5 years. With remission status in the model,
additional prognostic information was provided by serum
LDH, Ann Arbor stage and serum albumin. When the
analysis was repeated excluding remission status data from
the model, Ann Arbor stage proved to be the most signifi-
cant pre-treatment predictor of overall survival (Table V).
The 5-year survival rates for patients with stage I-IV disease
were 83, 61, 42 and 33% respectively (Figure 2). Additional
factors independently associated with a poor prognosis in the
pre-treatment assessment included a low serum albumin,
increasing patient age, an elevated gamma GT and the
presence of constitutional symptoms. Histological subtype in
Kiel was not significantly associated with overall survival
(Figure 3), and comparing survival rates between inter-
mediate grade and high grade histology revealed no signifi-
cant difference.
Attainment of CR
Sixty-five per cent of patients achieved CR, and their median
survival has not been reached. A multivariate analysis of
factors affecting the probability of achieving a CR revealed
Ann Arbor stage as the most important predictor of res-
ponse to therapy (P<0.001). All patients with stage I disease
achieved CR compared with only 47% of stage IV patients.
The multivariate analysis also showed that a low CR rate
was associated with the presence of constitutional symptoms
(P<0.001), increasing patient age (P=0.011), decreasing
serum albumin (P=0.034) and the presence of bulk disease
(P=0.029).
RFS and survivalfollowing CR
Thirty-six per cent of the complete responders have subse-
quently relapsed with 60% of relapses occurring within the
first 12 months. Sixty-one per cent of patients entering CR
are alive and free from disease at 5 years. In univariate
analysis (Table IV), an increased relapse rate was associated
with the presence of extranodal involvement (i.e. stage IV
disease, bone marrow infiltration and the number of extra
nodal sites of disease), a low serum albumin and an elevated
serum LDH. In multivariate analysis only Ann Arbor clini-
cal stage and serum LDH predicted for RFS and for overall
survival following CR. The association between stage and
RFS reflects the difference in relapse rate between localised
(stages I and II) and advanced disease (stages III and IV).
Patients with stage I and II disease showed 5-year RFS rates
of 76 and 71% respectively, compared with 52 and 47% for
the stage III and IV patients. Patients with a normal serum
level of LDH at presentation showed a 5-year RFS rate of
71% compared with 47% for those in whom the initial LDH
was elevated. The 5-year RFS for patients with centroblastic
tumours appeared superior (83%) to the other histological
categories (50-60%), but this difference did not reach statis-
tical significance.
FCM analysis
DNA ploidy was not significantly associated with response
to therapy or overall survival. However, proliferative index
(PI) (sum of cells in S and G2M) correlated with CR rate.
Seventy-one per cent of patients with a P1<20% achieved
CR compared with a 49% CR rate in those patients with a
Pl>20% (P=0.034). Despite this association with response
rate, PI was not significantly associated with overall survival
in univariate or multivariate analysis. The detailed results
will be published elsewhere.
Discussion
The accurate prognostic assessment of patients with high
grade NHL influences therapeutic strategy, improves stratifi-
cation in randomised studies and facilitates meaningful com-
parisons of results from different centres.
Attainment of CR
This study, in agreement with most other reported series, has
shown that the attainment of CR is the single most import-
ant indicator of prognosis (Fisher et al., 1981; Armitage et
al., 1982; Steward et al., 1984). In our patients the median
survival of the complete responders was in excess of 6 years,
whilc the partial responders and non-responders showed
median survival rates of 13 months and 2 months re-
spectively. This highlights the importance of determining
pretreatment variables that are predictive of response to
therapy. Ann Arbor stage was the most important predictor
of complete remission, but further subgroups of good and
poor responders could be identified using patient age, the
presence of bulk disease, constitutional symptoms and serum
albumin.
Ann Arbor staging
One purpose of this study was to re-evaluate the prognostic
relevance of the Ann Arbor system for clinical staging in
high grade NHL. Our results show that in the pre-treatment
assessment clinical stage is the most important predictor of
response to therapy, RFS and overall survival (Figure 2) and
this despite the fact that all stage I and the majority of stage
II patients received less intensive chemotherapy than the
stage III and IV patients. Armitage et al. (1982), in their
study of 75 patients with diffuse histiocytic lymphoma,
found that clinical stage was not an independent predictor of
response to therapy, overall survival or disease-free survival.
However, their group included only two stage I patients andNON-HODGKIN'S LYMPHOMA 279
Table IV Prognostic evaluation of factors using univariate analysis
CR Overall Survival
survival RFS following CR
% P (P) (P) (P)
Age (years)
<50 76
>50 58
Karnofsky performance
>90 82
80 73
70 50
A60 47
Clinical stage (Ann Arbor)
I 100
II 78
III 69
IV 47
Number of extra nodal sites
0 81
1 60
2+ 36
B symptoms
present 43
absent 80
Bulk disease
present 57
absent 75
Alkaline phosphatase
<lOOiul-1 73
> 100iu 1 53
AST
<40iul-1 69
>40iul-1 51
Gamma GT
<60iul-1 67
>60iul-P 47
Serum albumin
<40gl-1 51
>40gl-1 76
LDH
<500iul-1 72
>SOOiul-P 43
Haemoglobin
< 12gdl-1 47
>12gdl-1 70
Bone marrow involvement
present 45
absent 73
ESR
<20mmh-1 76
20-39mmh-1 71
>40mmh-1 39
Proliferative index
<20% 71
>20% 49
0.004
<0.0001
<0.0001
<0.0001
<0.0001
0.004
0.001
0.02
0.05
0.002
0.0001
<0.0001
<0.0001
<0.0001
n.s.
0.0004
0.006
0.02
0.0001 <0.0001
0.0008
0.002
0.0001
0.007
0.0002 <0.0001
<0.0001
0.034
0.0008
n.s.
n.s. n.s.
n.s. 0.04
0.002 0.001
0.0008 0.0009
n.s. n.s.
n.s. n.s.
n.s. n.s.
n.s. n.s.
n.s. n.s.
0.06 0.007
0.06 0.02
n.s. n.s.
0.0008 0.002
n.s. n.s.
n.s. n.s.
n.s. =not significant.
12 stage II patients. The Southeastern Cancer Study group
(Gams et al., 1985), analysing 296 patients, reported decreas-
ing CR rates with increasing stage of disease, but stage did
not prove to be an independent predictor of survival in the
multivariate analysis. Comparing stages I and II, Vokes et
al. (1985), reported a 94% RFS at 5 years in stage I patients
and a 56% RFS at 5 years in patients with stage II disease;
all patients receiving radiation as the primary treatment
modality, with chemotherapy being administered on relapse.
However, the Stanford group (Kaminski et al., 1986), report-
ing on 148 patients with localised large cell lymphoma
treated with initial radiotherapy, found only a borderline
difference in 5-year survival rates between stage I (56%) and
stage 11 (48%), and they showed a poor overall survival to
be associated with extralymphatic involvement, 'large'
volume disease (>10cm), age >60 years and gastrointestinal
involvement. A study of prognostic factors in stage I and II
disease by our own group has shown GI involvement, bulk
disease and serum albumin to be important (Mackintosh et
al., 1988). The prognostic value of the Ann Arbor distinction
between stage III and IV disease remains uncertain. Several
studies have reported similar survival figures for stage III
and stage IV patients (Koziner et al., 1982; Jagganath et al.,
1985; Todd et al., 1986; Laurence et al., 1982; Sweet et al.,
1980), but Nathwani et al. (1982), reporting the results on
162 patients from the Southwest Oncology Group, found a
significantly improved median survival in the stage III
patients (42 months) compared with patients with stage IV
disease (12 months), and these figures agree with our own
findings (33 months vs. 18 months).
Serum LDH and albumin
Serum LDH proved to be an important prognostic indicator,
and this has been reported in other series (Bierman et al.,
1957; Ferraris et al., 1979; Jagannath et al., 1986; Schneider
et al., 1980; Hagberg & Siegbahm, 1983). In this study,
although serum LDH was shown to be an independent280 R.A. COWAN et al.
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Figure 1 Overall survival - all patients.
Table V Cox's multivariate analysis of factors affecting survival
Variable P Favourable features
Remission status 0.3 x 10-18 Complete remission
LDH 0.000002 Low value
Clinical stage 0.010 Stage 1
Serum albumin 0.047 High value
Excluding remission status
Stage 0.6x10-8 Stage 1
Albumin 0.00009 High value
Age 0.029 Young age
Gamma GT 0.032 Small value
B. Symptoms 0.024 Absent
100 -
0
. _
cn
x 40-
20 -
Survival by stage
I.'l .,Il
"1 .-..-.. ....
.....................
III
I. IV
1 120 150
Figure 2 Overall survival - all patients by Ann Arbor clinical
stage.
Years
Figure 3 Overall survival - all patients by histological subtype
(Kiel). CC, centrocytic; D.CB/CC, centroblastic centrocytic
diffuse; CB, centroblastic; LB, lymphoblastic; IB, immunoblastic;
Unc., high grade unclassified.
predictor of overall survival (Table V), in the analysis of pre-
treatment prognostic factors (Table V), following the intro-
duction of serum albumin into the model serum LDH was
no longer significant. This illustrate the importance of
interpreting the results of multivariate analyses in the context
of the factors included in the analysis.
The prognostic relevance of serum albumin has been less
well documented. Our results show that serum albumin was
significantly associated with overall survival and with the
achievement of CR. H.S. Dhaliwal et al. (in preparation), in
their series of 103 patients with advanced high grade NHL,
also found serum albumin to be significantly associated with
overall survival, RFS and complete remission rate. Interest-
ingly, in our study we observed that overall survival corres-
ponded closely with the numerical values of serum albumin
and serum LDH irrespective of their 'normal' laboratory
range, and each biochemical 'marker' alone facilitated a
useful prognostic subdivision of patients (Figure 4).
Histological subtype
Histological subtype was not significantly associated with
prognosis, although there was a trend towards an improved
RFS in patients with centroblastic histology. This favourable
feature in the centroblastic patients is at variance with the
findings of Nabholtz et al. (1987), who reported a 5-year
survival of only 24.9% for their centroblastic patients com-
pared with our figure of 50% in patients of similarly
reported histology. This apparent discrepancy may reflect
differing criteria employed in the definition of the centro-
blastic and immunoblastic subdivisions in the Kiel system.
FCM analysis
Several studies have shown that DNA aneuploidy and high
proliferative activity are associated with high grade disease
(Christensson et al., 1986; Morgan et al., 1986; Juneja et al.,
1986), but few have investigated the prognostic significance
of DNA content within the category of high grade lym-
phoma. In concordance with two other series (Bauer et al.,
1986; Young et al., 1987) our results showed ploidy not to
be significantly associated with prognosis, but elevated proli-
ferative activity appeared to be an unfavourable prognostic
feature. Interestingly, in this study a raised PI (>20%)
correlated with a poor CR rate, a finding which initially may
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Figure 4 Overall survival. Subdivision of patients by serum albumin and LDH.
appear surprising in the context of the increased sensitivity
of cycling cells to ionising radiation and cytotoxic drugs.
However, other factors associated with high proliferative
rates may play an important part in tumour response. These
include neoplastic cell repopulation between courses of
chemotherapy or between fractions of radiotherapy, and the
increased probability of the emergence of 'resistant' clones in
high proliferative tumours. In contrast to the series from
Chicago and Sydney, the association of PI with response rate
in our study did not translate to a significantly reduced
overall survival.
In a prognostic factor analysis encompassing patients of
all stages, it is assumed that similar prognostic factors apply
irrespective of whether the disease is localised or advanced.
This, however, may be inaccurate, and the prognostic impact
of a particular variable may manifest in only a subgroup of
patients, and be masked when examining the total patient
population. The data from patients with stage I and II
disease and those with stage III and IV disease have been re-
analysed separately, and the results will be published
(Mackintosh et al., 1988; Cowan et al., in preparation).
This study serves to illustrate the prognostic importance of
the Ann Arbor staging system in patients with high and
intermediate grade NHL and has demonstrated factors
which when used in conjunction with clinical stage improve
our prognostic assessment of patients.
The authors wish to thank Mrs Dorothy Brown, our data manager,
without whose careful work this study would not have been
possible.
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